Responses
Clinical science
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 8 April 2015
- Published on: 8 April 2015Ranibizumab for neovascular AMD in eyes with good baseline visual acuity.Show More
We read with interest and congratulate Lee et al1 on publishing the largest study to date on visual outcomes reported upto 36 months, with intravitreal ranibizumab treatment for neovascular age related macular degeneration (AMD). However we do not agree with their conclusion that this is the first publication to focus on the visual outcomes on this subgroup of patients, excluded from treatment by the NICE UK criteria. O...
Conflict of Interest:
None declared.